Abstract
The advent of receptor binding techniques has provided new ways of studying the mechanism of action of drugs. In vitro radioligand binding is now currently applied to investigate the specificity or multiple action of compounds. By using the same technique, the binding affinity of a drug can be measured for a variety of neurotransmitter, drug, peptide and ion channel receptor binding sites, providing the drug’s receptor binding profile (Leysen et al. 1981; Leysen 1984). However, in vitro receptor binding is only the initial step in the investigation of drug-receptor interactions. Investigations in vivo are required to allow evaluation of how and where a drug acts. In fact, the study of drug-receptor interactions comprises three main stages: (a) in vitro radioligand receptor binding; (b) in vivo receptor binding, providing information on the accessibility of the drugs to the receptors localized in various central and peripheral tissues, on the drug potency for occupying various receptors, on the duration of receptor occupation and on the relationship between the degree of receptor occupation and pharmacological effects; and (c) the study of receptor regulation: the effect of chronic drug treatment on receptor alterations compared with alterations in functional responses in vivo.
In this article, we will illustrate the three stages of investigation of receptor interactions and discuss the relevance and importance of the findings, using as examples three drugs known in psychopharmacological research: (a) the neuroleptic haloperidol, a prototype of a dopamine D2 antagonist: (b) Setoperone, a potential antipsychotic agent with very potent serotonin S2 and moderate D2 antagonistic activity (Ceulemans et al. 1985; Leysen et al. 1986); and (c) ritanserin, a potent and long-acting S2 antagonist (Leysen et al. 1985), which has revealed therapeutic activity in dysthymia and negative symptoms of schizophrenia (Reyntjens et al. 1986; Gelders et al. 1986). Particular attention will be paid to the problem of receptor regulation. We challenge the general applicability of the receptor regulation theory, which states that persistent receptor stimulation causes desensitisation and receptor downregulation, whereas chronic deprivation of receptor stimulation leads to supersensitivity and receptor upregulation. Recent research has revealed that the theory does not hold for S2 receptor alterations, which were found to downregulate following chronic receptor blockade.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Blackshear MA, Friedman RL, Sanders-Bush E (1983) Acute and chronic effects of serotonin (5HT) antagonists on serotonin binding sites. Naunyn Schmiedebergs Arch Pharmacol 324: 125–129
Campbell A, Baldessarini RJ, Teicher MH, Kula NS (1985) Prolonged antidopaminergic actions of single doses of butyrophenones in the rat. Psychopharmacology 87: 161–166
Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens ASM, Janssen PAJ (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85: 329–339
Creese I, Snyder SH (1980) Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol 24: 89–94
Creese I, Burt DR, Snyder SH (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197: 596–598
De Chaffoy de Courcelles D, Leysen JE, Roevens P, van Belle H (1986) The serotonin-S2 receptor: a receptor-transducer coupling model to explain insurmountable antagonist effects: Drug Dev Res 8: 173–178
Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine- induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increase in D-l receptors. Biochem Pharmacol 32: 2921–2927
Gandolfi O, Barbaccia ML, Costa E (1984) Comparison of iprindole, imipramine and mianserin action on brain serotonergic and beta adrenergic receptors. J Pharmacol Exp Ther 229: 782–786
Gandolfi O, Barbaccia ML, Costa E (1985) Different effects of serotonin antagonists on 3H-mianserin and 3H-ketanserin recognition sites. Life Sci 36: 713–721
Gelders Y, Vanden Bussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol [Suppl 4] 9: 325–327
Haase HJ (1978) The purely neuroleptic effects and its relation to the “neuroleptic threshold”. Acta Psychiatr Belg 78:19–36
Hall H, Ross SB, Sallemark M (1984) Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long-term effects of antidepressants on β-adrenoceptors and 5-HT2 binding sites in the rat cerebral cortex. J Neural Transm 59: 9–23
Hyttel J, Fredericson Overo K, Arnt J (1984) Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 83: 20–27
Katz B, Thesleff S (1957) A study of the “desensitization” produced by acetylcholine at the motor end plate. J Physiol (Lond) 138: 63–80
Laduron PM, Janssen PFM, Leysen JE (1978) Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol 27: 317–321
Leysen JE (1984) Receptors for neuroleptic drugs. In: Burrows GD, Werry JS (eds) Advances in human psychopharmacology 3. Jai, London, pp 315–356
Leysen JE (1987) The use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AA, Blake GB, Juorio AV (eds) Drugs as tools in neurotransmitter research. Humana, Clifton (Neuromethods, neuropharmacology, vol 2) (in press)
Leysen JE, Gommeren W (1984) The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method. J Recept Res 4: 817–845
Leysen JE, Gommeren W (1986) Drug-receptor dissociation time, new tool for drug research: receptor binding affinity and drug-receptor dissociation profiles of serotonin-S2, dopamine- D2, histamine-H1 antagonists, and opiates. Drug Dev Res 8: 119–131
Leysen JE, Janssen PAJ (1987) Specificity of ligands used in psychiatric research. In: Sen AK, Lee T (eds) Receptors and ligands in psychiatry and neurology, vol 1. Cambridge University Press, Cambridge (in press)
Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry. Plenum, New York, pp 331–361
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168–171
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015–1022
Leysen JE, Van Gompel P, Verwimp M, Niemegeers CJE (1983) Role and localization of serotonin2 (S2)-receptor-binding sites: effects of neuronal lesions. In: Mandel P, DeFeudis FV (eds) CNS receptors–From molecular pharmacology to behavior. Raven, New York, pp 373–383
Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin. A very potent and long-acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611
Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PAJ (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 88: 434–444
Leysen JE, Van Gompel P, Gommeren W, Laduron PM (1987) Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 214–224 (Psychopharmacology series, vol 3 )
Lipinski JF, Zubenko GS, Cohen BM, Barreira PJ (1984) Propranolol in the treatment of neuro-leptic induced akathisia. Am J Psychiatry 141: 412–415
Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215: 582–587
Reyntjens A, Gelder YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8: 205–211
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313
Seeman P, Grigoriadis D (1987) Dopamine receptors in brain and periphery. Neurochem Int 10: 1–25
Snyder SH, Peroutka SJ (1982) A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatry 15: 131–134
Strange PG (1987) Dopamine receptors in the brain and periphery: “state of the art”. Neurochem Int 10: 27–33
Tarsy D, Baldessarini RJ (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13: 927–940
Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system in the rat brain. Acta Physiol Scand [Suppl 367] 82: 69–93
Van Wielink PS, Leysen JE (1983) Farmacologische keuzecriteria voor neuroleptica. Tijdschr Geneesmiddelenonderz 8: 1984–1997
Vetulani J, Starwarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments. Arch Pharmacol 239:109114
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Leysen, J.E., Gommeren, W., Janssen, P.F.M., Van Gompel, P., Janssen, P.A.J. (1988). Receptor Interactions of Dopamine and Serotonin Antagonists: Binding In Vitro and In Vivo and Receptor Regulation. In: Casey, D.E., Christensen, A.V. (eds) Psychopharmacology: Current Trends. Psychopharmacology Series, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73280-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-73280-5_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73282-9
Online ISBN: 978-3-642-73280-5
eBook Packages: Springer Book Archive